MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$15.09 USD
-0.26 (-1.69%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $15.08 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
MiNK Therapeutics, Inc.'s return on equity, or ROE, is -665.42% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.12%. While this shows that INKT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
INKT 15.09 -0.26(-1.69%)
Will INKT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INKT
New Strong Sell Stocks for August 22nd
INKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INKT
Is INKT poised for gains? 20 Day Moving Average Support shows up after sliding 1.69%
Crossed Above 20 Day Moving Average appears for INKT after 7.79% move
Is INKT showing downside potential? 20 Day Moving Average Resistance shows up after sliding 2.4%
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases